We are looking at individuals with a rare gene problem that causes their kidneys to pee out excessive phosphate. The gene is called SLC34A3 and it controls how the kidney handles phosphate, an important component of bone. This can lead to bone problems like early arthritis, and this can lead to kidney problems like kidney stones. We want to understand more about this condition and how it affects people.

This study is to assess the safety, tolerability and clinical efficacy of an investigational islet cell infusion, called VX-880. This study consists of a screening visit up to 60 days before receiving the infusion and a procedure to infuse the investigational treatment. You will need to attend follow-up visits monthly after the infusion for the first year and about every three months after for approximately five years. You will also receive several medicines before, during, and after the infusion of the islet cells and will be asked to take medicines for the entire duration of the study. You will be monitored throughout the study using continuous glucose monitor, which will be provided to you.

The study drug REGV131-LNP1265 is being developed to overcome the limitations of current gene therapies by inserting a functional F9 sequence into the albumin gene in liver cells. This treatment will prevent bleeding by restoring the production of functional Factor IX (9) activity to normal or near normal levels, eliminating the need for FIX replacement. The effects of REGV131-LNP1265 are intended to be irreversible and lifelong. In other words, this treatment is meant to be a cure for hemophilia B.

There is an urgent need to understand the role of therapeutic dietary interventions on the treatment of inflammatory bowel disease (IBD). This study explores the efficacy of a Therapeutic Dietary Intervention (TDI) compared to conventional management (CM) to induce steroid-free clinical remission at week 13 in patients with active, mild-to-moderate Crohn’s Disease. In this 3-year study, conducted at the University of Calgary and the University of Alberta, eligible participants will be randomly allocated in a 2:1 ratio to either the intervention group (CD-TDI) or conventional management (CM) alone (i.e., control group) for 13-weeks. Blood and stool samples will be collected to assess the effect of the dietary intervention.

The FOCUS study is being done to see if a medicine called semaglutide can reduce the risk of retinopathy progression in people with type 2 diabetes.

People with chronic heart failure are often prescribed medications to help manage their condition. This study is testing how well a drug called finerenone works and how safe it is for people with heart failure who cannot take a class of medications known as mineralocorticoid receptor antagonists (MRAs). MRAs are commonly used in treating heart failure, but some patients can't use them due to side effects or other health issues. This study is looking at whether finerenone which is a newer MRA medication could be a good alternative for those patients.

The purpose of this study is to investigate the use of portable oxygen during exercise in individuals with fibrotic interstitial lung disease who become hypoxemic (low oxygen in the blood) during exertion. Individuals will be allocated into a control group (no oxygen provided), or an intervention group (portable oxygen concentrator to be used during exercise) for 8 weeks. Measurements of exercise tolerance, blood vessel function, inflammation, and heart function will be taken at baseline, at the end of the intervention, and 2 weeks after the intervention.

To scale up and implement the CPIN system, thereby improving how to engage in practice based digital patient communication, education and collection of patient experience measures and feedback. Information needs to inform patient education and communication and health services in practices and regions across Canada will also be improved by this study. We will continue to implement the CPIN system using an iterative cycle of testing and improving our intervention, to contribute to a learning health system for primary care and health system leads at all levels.

RSV is a common cause of respiratory tract infection, which involves the passage formed by the mouth, nose, throat, and lungs. It is contagious and can be easily spread. Vaccines prepare your immune system for fighting illnesses by causing your body to make antibodies. Antibodies are special proteins in the blood that help to protect you from infectious diseases caused by bacteria and viruses. This is a Phase 3 clinical trial to study the investigational vaccine called mRNA-1345, for the prevention of RSV. It has not yet been approved by Health Canada. The main goals of this trial are to understand the safety and tolerability of the trial vaccine.

Cardiovascular disease is common among people with kidney failure. Though often not recognized, these circulatory problems often affect the blood vessels of the legs resulting in difficulty walking, foot wounds, and in some cases, amputation. However, we do not have accurate screening tests to identify circulatory problems at an early stage, before complications develop. We propose that the smaller blood vessels in the muscle could be tested to detect circulatory problems before complications develop. Before we test whether these novel tests can prevent complications from poor leg circulation, we will first use this study to see if these tests are acceptable to patients and practical to do.